There was a difference of @ % or less in class-specific adverse events associated with anti-VEGF therapy ( hypertension , proteinuria , wound-healing complications , thrombotic events , gastrointestinal perforations ) , except bleeding , which was more common in the placebo group than in the trebananib group ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .